News

Novartis receives approval for Cosentyx, their biologic treatment for enthesitis-related arthritis and juvenile psoriatic arthritis, in children and adolescents.

Patients with rheumatoid arthritis often have lung conditions. How much do you know about the risks of lung disease associated with rheumatoid arthritis? Test your knowledge with this quiz.

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending December 17, 2021.

Cannabidiol (CBD) may be used separately or in conjunction with standard treatment to reduce symptoms of juvenile idiopathic arthritis.

“Although many different autoantibodies have been investigated in SLE, only a limited number of autoantibodies are being used in clinical practice,” investigators stated. “Due to these limitations, there has been great interest in the discovery of new autoantibodies that can be used in clinical practice.”

The US FDA approved upadacitinib (15 mg daily) for the treatment of adults with active psoriatic arthritis with inadequate response to at least 1 TNF blocker.

Test your knowledge of the treatment and management of rheumatoid arthritis with our latest RA quizzes.

"Understanding the effects of the pandemic on specific areas of health care is crucial for future planning in both the immediate and longer term," stated investigators.

Smoking increased the risk of developing malar rash and mucosal ulcers as well as increasing the likelihood of experiencing migraine, Raynaud’s phenomenon, and arthritis symptoms.

Women with systemic lupus erythematosus are more likely to have accelerated progression of atherosclerosis. Recognizing the risk factors, such as larger waist circumference and higher fasting glucose levels, may be an important step in preventing this condition.

“Preliminary evidence has suggested that an exercise training could be effective in improving physical function and quality of life in juvenile dermatomyositis, without exacerbating the disease,” investigators stated.

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending December 10, 2021.

Investigators theorized that this questionnaire, in conjunction with autoantibody determination, could help screen for SLE in the early stages of the disease.

Jessica Walsh, MD, explains the importance of understanding treatment satisfaction and decision-making in patients with axial spondyloarthritis based on patient-reported outcomes.

Crohn’s disease inflames the gastrointestinal tract and causes consistent abdominal pain and diarrhea. Upadacitinib (AbbVie), a reversible Janus kinase (JAK) inhibitor, may be able to help patients achieve clinical remission.

Selective Janus kinase (JAK) inhibitor, upadacitinib, is now intended for adults with moderate-to-severe rheumatoid arthritis (RA) who have had inadequate response or intolerance to at least 1 tumor necrosis factor (TNF) blocker.

Rheumatoid arthritis often requires long-term treatment with disease-modifying antirheumatic drugs (DMARDs), but tapering and even cessation of DMARDs can be considered for patients in remission. Test your knowledge of use of DMARDs in patients in remission with this quiz.

Previous studies examining whether inflammatory disease was associated with an increased risk of Alzheimer's disease yielded mixed results.

Guselkumab is the first and only selective interleukin inhibitor therapy in the US that's approved for both moderate-severe plaque psoriasis and active psoriatic arthritis regardless of prior TNFi exposure.

Andrew Concoff, MD, explores the benefits of a gel that significantly improves clinical outcomes for patients with rheumatoid arthritis and decreases the need for concomitant medications.

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending December 3, 2021.

“Managing pain is an important treatment goal in patients with ankylosing spondylitis, however, pain is often underestimated by clinical disease activity scoring tools, and 20% to 30% of patients report pain despite treatment with TNFis,” investigators stated.

Philip Mease, MD, explains the recent Phase 3 data from the DISCOVER-1 and DISCOVER-2 clinical trials which demonstrated guselkumab inhibited radiographic progression, and improved symptoms and pain in patients with active psoriatic arthritis (PsA).

A correlation between disease activity and overall hand functionality was discovered in patients with psoriatic arthritis.

November's endocrine month in review features stories on the Build Back Better Act, a recent review from the IOF, data from Kidney Week 2021, and more.

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending November 26, 2021.

Ana-Maria Orbai, MD, FACR, MHS, explains how guselkumab improved PROMIS-29 scores in patients with psoriatic arthritis.

Mithu Maheswaranathan, MD, discusses the association of health literacy in terms of both clinical and self-reported outcomes for patients with systemic lupus erythematosus.

Despite the increasing trend of PRP in knee osteoarthritis, most clinical guidelines do not recommend it due to a lack of evidence on its efficacy.

Robert Terkeltaub, MD, explains the results from a phase 2, dose-finding study to determine the safety and efficacy of tigulixostat in patients with gout.